Maze Therapeutics CSBO Atul Dandekar Sells 6,434 Shares

What Happened

• Atul Dandekar, Chief Strategy & Business Officer (CSBO) of Maze Therapeutics (MAZE), sold a total of 6,434 shares in open-market transactions on Sept 2–3, 2026, generating about $168,811 in proceeds. The sales were reported on a Form 4 filed Sept 4, 2026.
• Individual reported sales: 2,800 shares at $26.38 ($73,853); 391 shares at $27.12 ($10,604); 3,207 shares at $26.01 ($83,425); and 36 shares at $25.81 ($929). The filing notes these sales were made to satisfy tax withholding obligations tied to RSU vesting (routine tax-withholding sale).

Key Details

• Transaction dates: Sept 2, 2026 and Sept 3, 2026; Form 4 filed Sept 4, 2026 (timely filing).
• Prices: reported as weighted averages; underlying trade-price ranges in filing span roughly $25.743 to $27.40 per share across the reported lots.
• Total shares sold: 6,434; total proceeds: approximately $168,811.
• Reason: tax withholding on vested restricted stock units (routine; tax-withholding code).
• Shares owned after transaction: not specified in the excerpt provided.
• Footnotes: filing states weighted-average prices and that the reporting person will provide per-price breakdowns on request to the company, shareholders, or SEC staff.

Context

• These were tax-withholding sales tied to RSU vesting (common, administrative transactions). Such sales typically do not signal a deliberate investment decision by the insider.